Health Discovery Corporation (OTCBB: HDVY) (“HDC”) is pleased to announce that D. Paul Graham, Chief Executive Officer of Graham Capital Partners, LLC, has joined the Board of Directors effective immediately.

“To be able to attract someone of Paul Graham’s background and experience to join our Board of Directors is a real coup,” said Dr. Barnhill. “We’re delighted to have Paul’s quarter century of corporate governance, management experience and financial acumen at the service of the board on behalf of the shareholders,” said Dr. Barnhill.

“I am proud to join the board of Health Discovery Corporation. I look forward to working with the Board of Directors to advance the robust technology platform and exceptional pipeline of products that the Company has to offer,” said Mr. Graham.

Mr. Graham has had for over 24 years a passion and focus on mergers and acquisitions (M&A) and leadership excellence within the small-to-middle markets.

In 1997, after a successful 12-year career with one of Canada’s premier transportation companies, Mr. Graham opened offices in Toronto, Canada to bring M&A expertise and value to an underserviced sector of the small-to-middle market. In 2002, he added offices in Atlanta, Georgia, and in 2005 opened offices in Savannah, Georgia.

Graham Capital Partners, LLC provides investment banking and business advisory services to the small-to-middle markets for companies achieving revenues between $10 million and $100 million. He has been involved in acquisitions, divestitures, and financings totaling over $200 million in transaction value in North America. Mr. Graham leads Graham Capital Partners in M&A and advisory mandates in North America, Europe and North Africa.

Mr. Graham was educated at Lakehead University and York University in the disciplines of accounting and finance. Mr. Graham serves in an advisory capacity and as a director for a number of privately held corporations and is a member of the Atlanta chapter of Association for Corporate Growth.

Mr. Graham replaces Michael Hanbury, Ph.D., who has resigned from the Board of Directors due to a cross country family relocation and the acceptance of new senior executive responsibilities with Spectrum Laboratory Network, Greensboro, North Carolina. Spectrum Laboratory Network, is a full-service regional medical laboratory providing laboratory services to over 7,000 physicians, 10 hospitals, nursing homes, home health, clinics, urgent care facilities, business and industries.

Spectrum Laboratory Network was purchased for $230 million in December 2009, by Welsh, Carson, Anderson & Stowe, New York, NY, one of the largest and most successful private equity investment firms in the United States with an investment focus exclusively in healthcare and information/business services.

In January 2010, Carilion Labs, based in Roanoke, Va., entered into an agreement to merge with Spectrum Laboratory Network to form a major laboratory company offering comprehensive clinical, anatomic pathology and esoteric testing services. The merger will create a new and stronger regional hospital laboratory company, serving 37 hospitals and 14,000 physicians in eight states, with more than 2,600 employees and annual revenues above $300 million.

Dr. Hanbury will continue to assist Health Discovery Corporation as an unpaid advisor.

“I have relied on Dr. Hanbury’s insights, judgment and wise counsel for many years,” said Stephen D. Barnhill, M.D., Chairman and CEO, Health Discovery Corporation. “While we will miss Mike Hanbury’s presence on the Board, we are delighted that he remains as a valued advisor and collaborator,” said Dr. Barnhill.

About Health Discovery Corporation

Health Discovery Corporation is a molecular diagnostics company that uses advanced mathematical techniques to analyze large amounts of data to uncover patterns that might otherwise be undetectable. It operates primarily in the emerging field of personalized medicine where such tools are critical to scientific discovery. Its primary business consists of licensing its intellectual property and developing its own product line of biomarker-based diagnostic tests that include human genes and genetic variations, as well as gene, protein, and metabolic expression differences and image analysis in digital pathology and radiology. For more information, see

Forward-Looking Statements

This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, the accuracy of which is necessarily subject to risks and uncertainties, including, without limitation, statements regarding future performance, opportunities and investments, and anticipated results in general. From time to time the Company may make other forward-looking statements relation to other matters, including without limitation, commercialization plans and strategic partnerships. Actual results may differ materially due to a variety of factors, including, among other things, the acceptance of our approach to applying mathematics computer science and physics into the disciplines of biology, organic chemistry and medicine and our products and technologies associated with those approaches, the ability to develop and commercialize new drugs, therapies or other products based on our approaches, and other factors set forth from time to time in the Company’s Securities and Exchange Commission filings.

All forward-looking statements and cautionary statements included in this document are made as of the date hereof based on information available to the Company as of the date hereof, and the Company assumes no obligation to update any forward-looking statement or cautionary statement.

Copyright Business Wire 2010